Circulating BRAF V600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma
Thyroid2018Vol. 28(3), pp. 328–339
Citations Over TimeTop 11% of 2018 papers
Carrie C. Lubitz, Tiannan Zhan, Viswanath Gunda, Salma Amin, Benjamin J. Gigliotti, Abbey Fingeret, Tammy M. Holm, Heather Wachtel, Peter M. Sadow, Lori J. Wirth, Ryan J. Sullivan, David J. Panka, Sareh Parangi
Abstract
This study shows the correlation of blood BRAFV600E levels in response to treatment in both an established animal model of thyroid cancer and in patients with BRAFV600E-positive tumors with all stages of disease. This assay represents an alternative biomarker in patients with positive thyroglobulin antibodies, and tumors, which do not express thyroglobulin.
Related Papers
- → Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well‐differentiated thyroid carcinoma(2007)22 cited
- → Value of the Estimation of Thyroglobulin Levels in the Surveillance of Treated Differentiated Thyroid Carcinoma(1984)9 cited
- Effect of Antithyroglobulin Antibody on Thyroglobulin About Differentiated Thyroid Cancer Patients(2006)
- [Thyroglobulin: usefulness and limits in monitoring patients with thyroid carcinoma].(2007)